NCT06248554View on ClinicalTrials.gov

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

PD-1 Inhibitors

Patients in the intervention group received post-operative adjuvant PD-1 inhibitor therapy, 240 mg intravenously every three weeks for nine cycles

Trial Locations (1)

430000

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan

All Listed Sponsors
lead

Chen Xiaoping

OTHER